NDC properties for "5000 MG Androgel 0.01 MG/MG Topical Gel" (RxCUI 1597130)
About this data
The tables show NDC propoerties for 5000 MG Androgel 0.01 MG/MG Topical Gel with the RxCUI 1597130
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for 5000 MG Androgel 0.01 MG/MG Topical Gel (RxCUI 1597130)
| MMSL_CODE | BD22847 |
|---|---|
| NDA | NDA021015 |
| RxCUI | 1597130 |
| SPL_SET_ID | 77215d87-ad22-4169-bd5f-a453f10b21ef |
| SPL_SET_ID | d466910c-9a76-44e8-8759-4717ec2c591f |
| VUID | 4029615 |
| Prescribable Synonym | AndroGel 1 % (50MG / 5GM) Transdermal Gel |
| RXNAV_STR | Androgel 1 % Transdermal Gel, 5 GM |
| RxNorm Name | 5000 MG testosterone 0.01 MG/MG Topical Gel [Androgel] |
| RxNorm Synonym | 5000 MG Androgel 0.01 MG/MG Topical Gel |
| RxNorm Synonym | Androgel 1 % Transdermal Gel, 5 GM |
| Related queries | Interactions (for RxCUI 1597130) |
NDC Properties
NDC Item 00051845001
| NDC 9 | 0051-8450 |
|---|---|
| NDC 10 | 0051-8450-01 |
| NDC Item | 00051845001 |
| Packaging | 5 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 697001 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2023-03-31 |
| Marketing effective time low | 2011-03-14 |
| Marketing status | COMPLETED |
| NDA | NDA021015 |
| Related queries | Properties for NDC 9 0051-8450 |
NDC Item 00051845030
| NDC 9 | 0051-8450 |
|---|---|
| NDC 10 | 0051-8450-30 |
| NDC Item | 00051845030 |
| Packaging | 30 PACKET in 1 CARTON (0051-8450-30) / 5 g in 1 PACKET (0051-8450-01) |
| DCSA | CIII |
| FDA SPL set id | 697001 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2023-03-31 |
| Marketing effective time low | 2011-03-14 |
| Marketing status | COMPLETED |
| NDA | NDA021015 |
| Related queries | Properties for NDC 9 0051-8450 |
NDC Item 00051845001
| NDC 9 | 0051-8450 |
|---|---|
| NDC 10 | 0051-8450-01 |
| NDC Item | 00051845001 |
| Packaging | 5 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 697001 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2023-03-31 |
| Marketing effective time low | 2011-03-14 |
| Marketing status | COMPLETED |
| NDA | NDA021015 |
| Related queries | Properties for NDC 9 0051-8450 |
NDC Item 00051845030
| NDC 9 | 0051-8450 |
|---|---|
| NDC 10 | 0051-8450-30 |
| NDC Item | 00051845030 |
| Packaging | 30 PACKET in 1 CARTON (0051-8450-30) / 5 g in 1 PACKET (0051-8450-01) |
| DCSA | CIII |
| FDA SPL set id | 697001 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2023-03-31 |
| Marketing effective time low | 2011-03-14 |
| Marketing status | COMPLETED |
| NDA | NDA021015 |
| Related queries | Properties for NDC 9 0051-8450 |